Search research articles
Contact Us
Filters
Showing results (51-60 of 95) with videos related to
Page
of 10
Sort By:
Angewandte Chemie (International Ed. in English)
|
February 18, 2025
Profiling Allosteric Modulators of CB<sub>1</sub>R with an Allosteric Fluoroprobe
Miroslav Kosar, Themiya Perera, Rudolf L Z Ganzoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
Identification of (<i>R</i>)-[<sup>18</sup>F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development
Yingfang He, Stefanie D Krämer, Uwe Grether, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 14, 2024
Exploration of (R)-[<sup>11</sup>C]YH168 as a PET tracer for imaging monoacylglycerol lipase in the brain: from mice to non-human primates
Yingfang He, MingQiang Zheng, Jiwei Gu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 8, 2010
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
Hans G F Richter, Gregory M Benson, Denise Blum, et al.
Nature Chemistry
|
November 23, 2023
Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learning
David F Nippa, Kenneth Atz, Remo Hohler, et al.
Molecules (Basel, Switzerland)
|
September 22, 2019
Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis
Richard Frederick Porter, Anna-Maria Szczesniak, James Thomas Toguri, et al.
Nature Communications
|
January 17, 2025
Author Correction: Prospective de novo drug design with deep interactome learning
Kenneth Atz, Leandro Cotos, Clemens Isert, et al.
Nature Communications
|
April 22, 2024
Prospective de novo drug design with deep interactome learning
Kenneth Atz, Leandro Cotos, Clemens Isert, et al.
Chemmedchem
|
August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases
Matthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Brain, Behavior, and Immunity
|
May 4, 2025
Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's disease
Leyre Ayerra, Miguel Angel Abellanas, Clara Vidaurre, et al.
Page
of 10
Search research articles
Search
Showing results (51-60 of 95) with videos related to
Sort By:
Page
of 10
Angewandte Chemie (International Ed. in English)
|
February 18, 2025
Profiling Allosteric Modulators of CB<sub>1</sub>R with an Allosteric Fluoroprobe
Miroslav Kosar, Themiya Perera, Rudolf L Z Ganzoni, et al.
Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|
January 2, 2024
Identification of (<i>R</i>)-[<sup>18</sup>F]YH134 for Monoacylglycerol Lipase Neuroimaging and Exploration of Its Use for Central Nervous System and Peripheral Drug Development
Yingfang He, Stefanie D Krämer, Uwe Grether, et al.
European Journal of Nuclear Medicine and Molecular Imaging
|
December 14, 2024
Exploration of (R)-[<sup>11</sup>C]YH168 as a PET tracer for imaging monoacylglycerol lipase in the brain: from mice to non-human primates
Yingfang He, MingQiang Zheng, Jiwei Gu, et al.
Bioorganic & Medicinal Chemistry Letters
|
December 8, 2010
Discovery of novel and orally active FXR agonists for the potential treatment of dyslipidemia & diabetes
Hans G F Richter, Gregory M Benson, Denise Blum, et al.
Nature Chemistry
|
November 23, 2023
Enabling late-stage drug diversification by high-throughput experimentation with geometric deep learning
David F Nippa, Kenneth Atz, Remo Hohler, et al.
Molecules (Basel, Switzerland)
|
September 22, 2019
Selective Cannabinoid 2 Receptor Agonists as Potential Therapeutic Drugs for the Treatment of Endotoxin-Induced Uveitis
Richard Frederick Porter, Anna-Maria Szczesniak, James Thomas Toguri, et al.
Nature Communications
|
January 17, 2025
Author Correction: Prospective de novo drug design with deep interactome learning
Kenneth Atz, Leandro Cotos, Clemens Isert, et al.
Nature Communications
|
April 22, 2024
Prospective de novo drug design with deep interactome learning
Kenneth Atz, Leandro Cotos, Clemens Isert, et al.
Chemmedchem
|
August 1, 2015
Novel Triazolopyrimidine-Derived Cannabinoid Receptor 2 Agonists as Potential Treatment for Inflammatory Kidney Diseases
Matthias Nettekoven, Jean-Michel Adam, Stefanie Bendels, et al.
Brain, Behavior, and Immunity
|
May 4, 2025
Activation of central cannabinoid type 2 receptors, but not on peripheral immune cells, is required for endocannabinoid-mediated neuroprotection in Parkinson's disease
Leyre Ayerra, Miguel Angel Abellanas, Clara Vidaurre, et al.
Page
of 10